- Home
- HOLO vs VERU Comparison
HOLO vs VERU Comparison
Compare HOLO & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOLO | VERU |
|---|---|---|
| Founded | 2018 | 1971 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.8M | 41.7M |
| IPO Year | N/A | 1990 |
Fundamental Metrics
Financial Performance| Metric | HOLO | VERU |
|---|---|---|
| Price | $2.18 | $2.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | ★ 583.7K | 116.2K |
| Earning Date | 08-10-2023 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 13.81 | N/A |
| Revenue | ★ $44,840,587.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.16 | ★ N/A |
| Revenue Growth | ★ 37.10 | N/A |
| 52 Week Low | $2.02 | $2.10 |
| 52 Week High | $72.40 | $7.40 |
Technical Indicators
Market Signals| Indicator | HOLO | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 35.38 | 42.94 |
| Support Level | $2.02 | $2.22 |
| Resistance Level | $2.30 | $2.50 |
| Average True Range (ATR) | 0.17 | 0.19 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 18.18 | 15.00 |
Price Performance
Historical ComparisonAbout HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library. Geographically company is operating in single segment, China.
About VERU Veru Inc.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.